MESOMARK BLOOD TEST

In January 2007, the Food and Drug Administration (FDA) approved? the MESOMARK assay for monitoring r? response to treatment in the cells? pith? CNPF phasic and bi-m? Soth? liom malignant patients. A prot? Ine sp? Cific, or biomarkers, appeal? Soluble Mesothelin-Related Peptide (SMRP), May? Lib tre? R? in the blood by the cells of m? Soth? liom, cancer. By measuring the quantity? of SMRP in a? Chantillon blood, m? May sicians? be able to better monitor a patient \ 's progress. Based on the quantity? limit? e data? are currently available, the use of this test in May? tre b? n? fique but effective? did not? t? d? termin? yet. MESOMARK blood test has not yet? T? approved? for diagnosis pr? coce m? Soth? liom.

This test? T? approved? as a Humanitarian Use Device (HUD), which means that the m? doctors must follow certain trial procedures to b? n? benefit of their patients for testing. Once the m? Doctor is certified?, Information leaflets will be sent? Es? ? be distributed? s? each patient.

Those who wish to take part?

MESOMARK test will be invited? S? provide one or several? Chantillon blood. The? Chantillon blood will then be sent? ? a National Laboratory of r-f? rence for testing. In collaboration with other data? Es clinical and laboratory obtained by your m? Doctor, the d? Decisions about your treatment and care in May? Be simplified? E. May you stop testing? any time.

Co? Ts associ? S? the blood test in May MESOMARK not? be covered by health insurance, for construction? Therefore, May you? be required to pay the total? or part of the co? ts of their pocket. It is recommended v? verify aupr? s your insurer to d? whether coverage was available under your policy.